ALKS (Alkermes) Total Equity: $1,752 Mil (As of Mar. 2026)


ALKS Alkermes PLC ALKS
70 GF Score
Price $55.16
GF Value $31.33
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Alkermes Total Equity?

Alkermes ALKS +4.26% 70 Total Equity is $1,752 Mil as of Mar. 2026. GuruFocus rates ALKS with a GF Score™ of 70/100 and a GF Value™ of $31.33 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Alkermes's total equity for the quarter that ended in Mar. 2026 was $1,752 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Alkermes Total Equity Historical Data

* Premium members only.

The historical data trend for Alkermes's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes Total Equity Chart

Alkermes Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,112.58 1,043.75 1,202.69 1,464.98 1,819.30

Alkermes Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,511.58 1,624.58 1,733.43 1,819.30 1,751.53
ALKS
70GF Score
Alkermes PLC ALKS
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alkermes Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Alkermes's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=2486.993-667.698
=1,819

Alkermes's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=4258.076-2506.545
=1,752

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $1,752 Mil mean?
Alkermes (ALKS) has a Total Equity of $1,752 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Alkermes and its competitors.
Is Alkermes' Total Equity too high?
Alkermes' current Total Equity is $1,752 Mil. Overall, Alkermes has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alkermes' Total Equity compare to LNTH and HIMS?
Alkermes' Total Equity of $1,752 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Alkermes and its competitors. Alkermes's current Total Equity is $1,752 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkermes stock overvalued right now?
Based on GuruFocus' analysis, Alkermes (ALKS) is currently considered Significantly Overvalued. The stock's GF Value™ is $31.33, compared to a current price of $55.16 — trading 76% above its estimated fair value. The current Total Equity is $1,752 Mil. Alkermes' overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Alkermes (ALKS), the current Total Equity is $1,752 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alkermes (ALKS) Overvalued in 2026?

Based on GuruFocus' analysis, Alkermes stock appears to be overvalued. The current stock price of $55.16 is trading 76% above its estimated GF Value™ of $31.33. GuruFocus considers Alkermes to be Significantly Overvalued.

Key valuation signals for ALKS:

  • Total Equity: $1,752 Mil
  • GF Value™: $31.33 vs. price of $55.16 (76% above fair value)
  • GF Score™: 70/100 with 8 warning signs

No single metric tells the full story. See the ALKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alkermes Business Description

Other Exchanges 8AK:Germany
Address 1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
70GF Score

Get the complete analysis for ALKS

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$55.16
Price
$31.33
GF Value